Literature reports the use of TERT promoter mutation screening programs in thyroid tumors in order to select patients who would benefit from adjuvant treatment and closer follow-up (21), since many studies related the presence of these mutations with poor prognosis (22–25). This evidence concerns the gene TERT and thyroid tumor.